Patents Assigned to Kindex Pharmaceuticals, Inc.
  • Tetrahydro-isohumulone derivatives, methods of making and using
    Patent number: 10343977
    Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 9, 2019
    Assignee: KINDEX PHARMACEUTICALS, INC.
    Inventors: Veera Konda, Jan Urban, Anuradha Desai, Clinton J. Dahlberg, Brian J. Carroll
  • Tetrahydro-isohumulone derivatives, methods of making and using
    Patent number: 9828331
    Abstract: The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPAR? modulation such as diabetes.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: November 28, 2017
    Assignee: KINDEX PHARMACEUTICALS, INC.
    Inventors: Veera Konda, Jan Urban, Anuradha Desai, Clinton J. Dahlberg, Brian J. Carroll
  • Methods of synthesizing alpha acids and substantially enantiomerically pure compositions thereof
    Patent number: 9340479
    Abstract: Methods of synthesizing a cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one (“KDT500”) derivative are provided. Such methods may be used to synthesize any desired KDT derivative. In one embodiment, the KDT500 derivative is KDT501.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: May 17, 2016
    Assignee: KINDEX PHARMACEUTICALS, INC.
    Inventor: Clinton Dahlberg
  • Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl) cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
    Patent number: 8829056
    Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: September 9, 2014
    Assignee: Kindex Pharmaceuticals, Inc.
    Inventors: Brian J. Carroll, Gary Darland, Anuradha Desai, Veera Konda, Clinton J. Dahlberg, Jan Urban